The physiological effects of glucagon-like peptide-1 (GLP-1) are exciting because of the potential clinical relevance in treating two of the major abnormalities that contribute to type 2 diabetes: impaired insulin secretion and excessive glucagon secretion. GLP-1 also appears to have effects on gastric emptying and appetite suppression. Join host Dr. Steven Edelman and his guest Dr. Robert Henry, professor of medicine at the University of California, San Diego, and chief of both the section of endocrinology, metabolism and diabetes and the Center for Metabolic Research at the VA Medical Center in San Diego.
advertisement
New Developments in Incretins and SGLT Inhibitors
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Recommended
Details
Presenters
Overview
The physiological effects of glucagon-like peptide-1 (GLP-1) are exciting because of the potential clinical relevance in treating two of the major abnormalities that contribute to type 2 diabetes: impaired insulin secretion and excessive glucagon secretion. GLP-1 also appears to have effects on gastric emptying and appetite suppression. Join host Dr. Steven Edelman and his guest Dr. Robert Henry, professor of medicine at the University of California, San Diego, and chief of both the section of endocrinology, metabolism and diabetes and the Center for Metabolic Research at the VA Medical Center in San Diego.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
advertisement
Recommended
CME/CE
Implementing a Multidisciplinary Approach to Heart Failure: Patient Identification and Treatment Using Novel Device Therapy
0.25 credits
<p>Implementing a Multidisciplinary Approach to Heart Failure: Patient Identification and Treatment Using Novel Device Therapy</p>
CME/CE
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
0.25 credits
<p>Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective</p>
CME/CE
IgG4-RD Case Conversations: IgG4-related Autoimmune Pancreatitis and Cholangitis
0.25 credits
<p>IgG4-RD Case Conversations: IgG4-related Autoimmune Pancreatitis and Cholangitis</p>
CME/CE
Updates From the 7th World Symposium Task Force
1.00 credits
<p><span data-contrast="auto" xml:lang="EN-US">Updates From the 7th World Symposium Task Force</span><span data-ccp-props='{"201341983":0,"335559738":210,"335559739":210,"335559740":240}'> </span></p>
CME/CE
Spinal Muscular Atrophy: Optimizing the Management of Adults in the Era of Disease-Modifying Therapies
1.00 credits
<p>Spinal Muscular Atrophy: Optimizing the Management of Adults in the Era of Disease-Modifying Therapies</p>
CME/CE
TIME OUT: A Case-Based Deep Dive into the Challenges of ARIA Management
0.50 credits
<p>TIME OUT: A Case-Based Deep Dive into the Challenges of ARIA Management</p>
MinuteCE®
A Practical Guide to Prescribing in HF
0.75 credits
<p>A Practical Guide to Prescribing in HF</p>
MinuteCE®
Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
0.75 credits
<p><span data-contrast="auto" style="list-style-type: disc;" xml:lang="EN-US">Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies</span></p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?